To investigate antitumor mechanisms in interleukin (IL)-4 therapy, we established an IL-4-overexpressing MC38 murine colorectal cancer cell line (MC38-IL4). As a therapy against established tumors, MC38-IL4 cells were inoculated contralaterally 7 days after wild-type (MC38-WT) cells had been injected, significantly reducing growth of wild-type tumors (P ¼ 0.030). Immunohistochemical analysis showed numerous granulocytes infiltrating wild-type tumors of MC38-IL4-inoculated mice. Injection of MC38-IL4 cells in leukocytedepleted mice confirmed that granulocytes were involved in IL-4-related primary antitumor effects. Inoculation of MC38-WT in leukocyte-depleted mice initially injected with MC38-IL4 suggested that T cells contributed to the antitumor effects. To investigate tumor-specific responses, we stimulated splenocytes of MC38-immune mice with MC38-IL4 cells in vitro, resulting in MC38-specific lysis (57.577.2%, effector to target ratio ¼ 20). Treatment of established wild-type tumors with MC38-IL4 in combination with interferon (IFN)-a-overexpressing MC38 cells (MC38-IFNa) significantly reduced the growth of wild-type tumors (P ¼ 0.009). In vitro IFN-g production by splenocytes from mice injected with both MC38-IL4 and -IFNa was greatly enhanced in comparison with MC38-IL4 alone, while IL-10 production was not increased. Thus, granulocytes concern early antitumor effects of IL-4 therapy. Subsequently, IL-4 induces longlasting, tumor-specific immune responses. IL-4 appears to promote a T-helper 1-type antitumor immune response, which is enhanced in cooperation with IFN-a. Gene Therapy (2005) 12, 733-741.
Introduction
Cellular immune responses are thought to be impaired in patients with advanced malignant tumors. To overcome such an immunosuppressed state, tumor-based vaccination in combination with cytokine gene therapy has been used in treatment of these tumors. This therapy is considered advantageous in that paracrine cytokine delivery by genetically modified tumor cells avoids problems of systemic toxicity and need not be directed at any specific tumor-associated antigen. Although many animal experiments and a few clinical trials involving cytokine gene therapy seemed to be successful, most clinical attempts have shown insufficient responses. Improvement of this therapy is needed to make it effective against malignant tumors.
Several studies of experimental models have suggested that a T-helper (Th)1-type response plays a critical role in antitumor therapy. We previously found that interferon (IFN)-a as well as interleukin (IL)-12 gene transduction of tumor cells effectively reduced tumorigenicity of poorly immunogenic colorectal cancer cells. In addition, IFN-a effectively elicits tumor-specific cytotoxic T lymphocytes (CTL) and induces long-lasting antitumor immune responses in vivo. IFN-a gene therapy in combination with IL-12 gene therapy was found to suppress outgrowth of established tumors. 1 However, Th2-type cytokines such as IL-4 also have been found to induce potent protective and therapeutic immune responses. [2] [3] [4] [5] IL-4 directs differentiation of Th0 lymphocytes toward the Th2 phenotype. 6, 7 Initially termed B cell growth factor or B cell stimulatory factor-1, 8 IL-4 plays a major role in B cell as well as T cell development. 8 Stimulation of B cells with IL-4 results in production of IgE, 9 which has been implicated in allergic reactions and responses induced by parasitic infection.
In addition to these varied functions, IL-4 has a direct inhibitory effect on tumor cell growth in vivo and in vitro. [10] [11] [12] Direct effects may depend on expression of IL-4 receptor, which has been reported to be present on a variety of carcinoma cells. 13 A reported antiangiogenic effect of IL-4 14 also may contribute to antitumor effects of IL-4 therapy. In addition, IL-4 activates endothelia in the tumor microenvironment, which increases infiltration by immune cells. 15 Previous data suggest that activities of nonadaptive immune effectors such as eosinophils and neutrophils are responsible for antitumor effects induced by IL-4. [16] [17] [18] With respect to cellular immunity against tumors, CD8-positive cells have been found to infiltrate regressing gliomas treated by IL-4 gene therapy. 19, 20 CD4-positive T cells also may be essential to the antitumor effects of IL-4. 21 Furthermore, IL-4 has been used widely to generate both human and murine dendritic cells (DC), which initiate and regulate immune responses as antigen-presenting cells. Recently, IL-4 has been reported to be involved in Th1-type immune response against tumors. IL-4 has been demonstrated to drive Th1 responses by inducing apoptotic death of DC2 (lymphoid DC) and maturing DC1 (myeloid DC). 22 In the presence of IL-4 and transforming growth factor-b, naïve CD4 + T cells can differentiate into Th1-type cells in vitro.
23 In addition, IL-4 has been suggested to induce Th1-type development by stimulating IL-12 production by DC (summarized in Okada and Kuwashima 24 ). Further understanding of mechanisms related to cytokine gene therapy is needed for effective and safe clinical application, aiming for a better response in patients with malignant tumors. To clarify the mechanism of IL-4 gene therapy against cancer, we established a colorectal cancer cell line genetically modified to secrete IL-4 and observed changes on tumorigenicity compared with nontransduced parental tumor cells. Then we evaluated the therapeutic effects against established parental cell tumors from inoculation with IL-4-overexpressing tumor cells. We also analyzed the antitumor effects induced by IL-4 gene therapy using immunohistologic staining of tumors and induction of tumorspecific T lymphocytes in splenocytes from mice immunized with IL-4-transduced tumor cells. Furthermore, we investigated the possibility of IL-4 gene therapy in combination with gene therapy involving Th1 cytokines, IL-12, and IFN-a.
Results

IL-4 gene transduction of tumor cells does not affect growth in vitro
A murine IL-4 gene was transduced retrovirally into MC38 tumor cells. After antibiotic selection with G418, production of murine IL-4 by the cells was confirmed with enzyme-linked immunosorbent assay (ELISA). IL-4-overexpressing MC38 (MC38-IL4) cells produced 359.87108.2 ng of IL-4/10 6 cells/48 h, while we could not detect IL-4 in culture supernatants from wild-type MC38 (MC38-WT) cells and neomycin-resistance genetransduced MC38 (MC38-Neo) cells. MC38-WT, -Neo, and -IL4 cells were seeded at 1 Â 10 5 cells/well in sixwell plates, and cell numbers per well were counted every 3 days in triplicate. The growth rate of MC38-IL4 did not differ from those of MC38-WT or -Neo cells (data not shown).
Transduction of IL-4 gene reduces tumorigenicity of MC38 cells
After syngeneic immunocompetent C57BL/6 (B6) mice were inoculated s.c. with 1 Â 10 5 WT, Neo, or MC38-IL4 cells, resulting tumor size was measured ( Figure 1 , Experiment 1). As shown in Figure 2 , transduction of IL-4 significantly reduced tumor growth from the inoculated cells compared with MC38-WT or -Neo in this poorly immunogenic tumor model (P ¼ 0.0162 versus WT, P ¼ 0.0085 versus Neo). Numbers in Figure 2 represent total numbers of tumor-free mice in three separate experiments on day 70 (35 days after the second Figure 1 Designs of experiments performed in this study. WT, wild-type MC38; Neo, neomycin-resistance gene-transduced MC38; IL4, IL-4-overexpressing MC38; rt, injection at the right flank; lt, injection at the left flank; Sac, sacrifice; Ab, antibody; CTL, cytotoxic T lymphocyte; ELISA, enzyme-linked immunosorbent assay. MC38-WT inoculation (2 mice/group). Tumor tissues were harvested 3 days after inoculation of genetically modified tumor (10 days after WT inoculation), and were exposed to anti-Gr-1, anti-CD4, and anti-CD8a antibody. Immunoreactive cells were counted in 10 fields using light microscopy ( Â 400) in a blinded fashion. Results are reported as the mean number of positive cells7s.d. For further analysis, we used antibodies to deplete leukocytes from MC38-immune mice, which were immunized with MC38-IL4, and subsequently inoculated with MC38-WT at the opposite side of initial (MC38-IL4) injection ( Figure Tumor-specific cytolysis was detected when splenocytes of MC38-immune mice were stimulated by IL-4-overexpressing tumor cells
We investigated the effects of IL-4 gene transduction on induction and propagation of tumor-specific CTL generated from immune mice. Splenocytes were harvested from mice that were tumor-free after an initial inoculation of MC38-IL4 cells and a subsequent inoculation of MC38-WT cells. Cells were then stimulated in vitro twice weekly with MC38-Neo or -IL4 cells. Cytolytic assays against MC38 and YAC-1 cells, which are sensitive to NK cells, were performed 7 days after the second stimulation ( Figure 1 Table 2 ). Combination therapy with MC38-IL4 plus -IFNa also suppressed the growth of established tumors somewhat more effectively than therapy with MC38-IL4 + -Neo, although the difference fell short of significance. We performed this experiment three times with similar results. Thus, additive antitumor effects from a combination of a Th1 cytokine (IFN-a) with a Th2 cytokine (IL-4) were observed in established wild-type tumors.
Production of IFN-g by splenocytes from MC38-immune mice was greatly enhanced by stimulation with IL-4-and IFN-a-overexpressing cells
We measured IFN-g and IL-10 production by splenocytes obtained from mice inoculated with MC38-IL4 or both MC38-IL4 and IFNa cells to investigate whether IL-4 promoted a Th1-or Th2-type immune response in combination with IFN-a. We inoculated mice with 
genetically modified MC38 cells, alone or in combination, and then, reinjected these mice with MC38-WT. Subsequently mice were killed; their splenocytes were harvested and simulated by various tumor cells in vitro.
After 7 days, we performed IFN-g and IL-10 ELISA in culture supernatant ( Figure 1 , Experiment 8). We prepared two mice per group. IFN-g production was clearly increased in the MC38-IL4 group (129.36 ng/ml) compared with the MC38-Neo group (6.05 ng/ml), while IL-10 production did not differ (Neo; 0.05 ng/ml, IL-4; 0.20 ng/ml). Furthermore, IFN-g production in the MC38-IL4 + -IFNa group was greatly enhanced (737.65 ng/ml) compared with the MC38-IL4 or -IFNa group ( Figure 7 ). This result suggested that IL-4 elicits a potent Th1-type response in combination with IFN-a.
Discussion
Gene therapy using tumor cells genetically modified to produce cytokines has been studied in several therapeutic models. IL-4, a representative Th2-type cytokine implicated in various aspects of immune responses, 24 has been used in several clinical trials 5,25-28 as well as experimental models 4, 29 for tumor therapies. Since our aim in this study is to explore the mechanisms of IL-4 gene therapy that might apply to subsequent clinical study, we performed several experiments using genetically modified tumor cell lines to overexpress IL-4. The possibility of cytokine gene-transduced tumor-based vaccination may depend on whether the cells can produce sufficient amounts of the desired cytokine. In this study, we established an IL-4-overexpressing tumor cell line that can produce a large amount of IL-4 (359.87108.2 ng/10 6 cells/48 h) that was likely to modulate immune responses more efficiently than in previous reports. 4 For clinical application, we need to develop a vector that can transduce genes efficiently to a patient's tumor cells.
In Immunohistologic analyses of the established tumors in mice treated with tumor cells genetically modified to secrete IL-4 implicated granulocytes in the primary response ( Figure 4 and Table 1) . Leukocyte-depletion experiments demonstrated that granulocytes play an important role in the IL-4 induced antitumor effects, and that neither CD4 + , CD8 + , nor NK cells were essential to the initial tumor rejection induced by IL-4 therapy (Figure 5a and b) . This observation is consistent with previous observations that IL-4 gene-transduced tumors induce inflammation characterized by infiltrating eosinophils and neutrophils. 2, 30, 31 In this study, infiltration by eosinophils was not confirmed in established tumors in mice treated with MC38-IL4; had we performed immunohistochemical analyses at different time points, such infiltration might have been detected. How IL-4 Then, we injected 1 Â 10 5 MC38-WT cells 2 weeks after the first inoculation. After 7 days, mice were killed, and splenocytes from these mice were simulated in vitro with each cytokine or control gene-transduced MC38 cells alone or in combination, corresponding to the first inoculation. After 7 days incubation, we measured (a) IFN-g and (b) IL-10 concentrations in the culture supernatant by ELISA. This experiment was repeated three times, and a representative result is shown.
IL-4 gene therapy for cancer J Eguchi et al
recruits or stimulates granulocytes in the tumor microenvironment is still unclear. In addition, although we previously speculated that IL-4 was antiangiogenetic in this model, 14 we presently did not detect any antiangiogenic effects by immunohistochemical analysis (unpublished data).
We According to our observations, we hypothesized the following sequence. IL-4 directly or indirectly recruits and activates granulocytes in the microenvironment of tumors to attack and kill the tumor cells in the primary response. DC then capture the necrotic or apoptotic tumor cells, and process them. After stimulation by tumor antigen-presenting DC, a tumor-specific cellular immune response would be induced. However, when we investigated DC infiltration in the established tumor tissues treated with IL-4-overexpressing tumor cells, we could not detect significant infiltration (unpublished data). Further investigation is required to clarify these issues.
Furthermore, IL-4 gene therapy in combination with gene therapy augmenting Th1-type cytokines, IFN-a or IL-12, significantly suppressed outgrowth of established wild-type tumors. In our previous study, we analyzed the antitumor effects of IFN-a and IL-12 gene therapy, demonstrating that IFN-a effectively elicits tumor-specific CTL, while IL-12 activates NK cells.
1 IL-4 produced by Th2-type cells has been suggested to suppress generation of Th1 cells. 32 IL-4 also has been reported to upregulate IL-4 receptor (a) expression in human mononuclear cells and B cells, while this receptor is significantly downregulated by IFN-a. 33 Although IFN-a thus seemed to antagonize IL-4 responses in these previous observations, we suspected that gene therapy combining a Th1 cytokine (IFN-a or IL-12) with IL-4 might offer additive benefit because individual cytokine gene therapy proved effective and mechanisms of antitumor effects appeared to differ between cytokines in our model. Our present results showed that both cytokines effectively elicited tumor-specific CD8 + cells, and also observed an additive antitumor effect from IL-4 together with IFN-a. We found that IFN-g production by splenocytes exposed in vivo and in vitro to genetically modified tumor cells was clearly increased in MC38-IL4-immunized mice compared with control mice, while IL-4 did not greatly enhance production of IL-10, a representative Th2-type cytokine. Although some specific Th2 cells have been reported to contribute to tumor regression by activating primed CD8 + CTL, 34 IL-4 appeared to stimulate and activate Th1-type immune response rather than Th2 in our model, as previously reported.
23,24 IFN-g production by splenocytes from mice immunized with IL-4-and IFN-a-transduced tumor cells was enhanced more than with IL-4 or IFN-a stimulation alone ( Figure  7) . Our result suggests that IL-4 promotes Th1-type T cell response in cooperation with IFN-a. To our knowledge, this is the first demonstration that IL-4 gene therapy in combination with IFN-a therapy effectively elicits antitumor immunity in vivo. Cross-inhibitory effects of IL-4 and IFN-g have been reported mainly in vitro or in the late phase of the immune response to chronic antigen exposure. 35 Whether an immune response is predominantly Th1 or Th2 seems to depend on a number of variables (mouse strain, kind of tumor, amount of tumor antigen, and amount of cytokine 36, 37 ). From our results, combination therapy with IL-4 and IFN-a may be a candidate for clinical cancer therapy.
From data in the previous 1 and present studies, although each cytokine gene monotherapy, such as IFN-a, IL-12, and IL-4, has therapeutic effects against established tumor, the antitumor effects are thought to be not potent enough to eradicate the advanced tumor. Thus, cytokine gene monotherapy needs some modification, such as combination with immunoadjuvants, for clinical application. We are now investigating the antitumor effects of IFN-a gene therapy in combination with DC-based immunotherapy. We believe that elucidation of antitumor mechanisms of immune therapies will lead to development of new effective therapies for malignant tumors.
Clinical use of this kind of tumor-based gene therapy may be limited because of the need to transduce genes in patients' tumor cells. To facilitate this, the method of cytokine gene delivery will need to be modified. In addition, since antitumor mechanisms of cytokines are complex, further study of combined cytokine gene therapies will be required prior to clinical trials.
Materials and methods
Mice
Female B6 mice, 6-8 weeks old, were purchased from Saitama Experimental Animals Supply (Saitama, Japan) for use in experiments at ages from 8 to 12 weeks. Mice were maintained in an animal care facility at Showa University.
Cell lines, culture medium, and reagents
The MC38 murine colorectal adenocarcinoma cell line, 38 the MCA205 fibrosarcoma cell line (both; B6 mouse origin), and YAC-1 lymphoma cells were maintained in RPMI 1640 medium supplemented with 10% heatinactivated fetal calf serum, 2 mM L-glutamine, 100 IU/ ml penicillin, 100 mg/ml streptomycin, 10 mM HEPES buffer, 1 mM minimum essential medium sodium pyruvate, and 0.1 mM minimum essential medium IL-4 gene therapy for cancer J Eguchi et al nonessential amino acids (complete medium (CM)) in a humidified incubator with 5% CO 2 in air at 371C. All cell culture reagents were purchased from Life Technologies (Gaithersburg, MD, USA). YAC-1 cells were used as target cells for assessing nonspecific killing in cytolytic assays.
Retroviral transduction and genetically modified tumor cell lines
MC38 tumor cells were transduced using retroviral vectors according to standard protocols 39 and selected for antibiotic resistance in CM containing 0.75 mg/ml. G418 (Sigma, St Louis, MO, USA). Construction of the retroviral vector, DFG-murine IL-4-neo, has been described in previous studies. 29, 40 Expression of murine IL-4 was confirmed by ELISA using a commercially available kit according to the manufacturer's instructions (mouse IL-4 ELISA, Endogen, Woburn, MA, USA). MC38-Neo cells, expressing the neomycin-resistance gene following retroviral transduction with MFG-Neo, were used as control cells. 41 Established MC38-IFNa and -IL12 have been described previously. 
Therapeutic models
To evaluate use of IL-4-overexpressing tumor cells in treating established tumors, we measured the size of established MC38-WT tumors in mice before and after treatment with genetically modified MC38 cells as previously described. 41 In brief, B6 mice first were injected in the right flank with MC38-WT cells (1 Â 10 5 cells s.c.). Injection of 1 Â 10 5 MC38-Neo, or -IL4 cells in the contralateral (left) flank, followed three times at 3-day intervals starting at day 7, when tumors had reached a cross-sectional area of 16-30 mm 2 ( Figure 1 , Experiment 2). Each experiment involved six mice per group. Tumor size was measured twice a week using vernier calipers. Experiments with the therapeutic model were performed three times.
Immunohistologic analysis
For leukocyte detection in tumor tissues, B6 mice were injected s.c. with 1 Â 10 5 MC38-Neo or -IL4 cells in the area surrounding the established wild-type tumor (same side) 7 days after inoculation of 1 Â 10 5 MC38-WT cells. Tumor tissues were harvested 3 days after inoculation of genetically modified tumor (10 days after WT inoculation; Figure 1 , Experiment 3), and were immediately embedded in optimal clotting temperature (OCT) compound (Tissue Tek, Elkhart, IN, USA) and frozen for sectioning. Serial 5-mm sections were exposed to antiGr-1, anti-CD4, and anti-CD8a antibody (Nippon Becton Dickinson, Tokyo, Japan). Rat IgG2a (Nippon Becton Dickinson) was used as a control antibody. Immunostaining was completed with a Vectastain ABC kit (Vector, Burlingame, CA, USA). Immunoreactive cells were counted in 10 fields using light microscopy ( Â 400) in a blinded fashion.
Antibody-mediated depletion of leukocytes in vivo
To determine the role of the immune system in reduction of tumor growth in vivo, CD4 + T cells, CD8 + T cells, asialo-GM1 + cells, or granulocytes were depleted using the respective antibody as reported previously. 1, 42 Culture medium from hybridomas producing the following antibodies was used at appropriate dilutions/concentrations: anti-CD4 (GK1.5, TIB207; American Type Culture Collection (ATCC); Manassas, VA, USA), and anti-CD8 (2.43, TIB210; ATCC). For depletion of NK cells, antiasialo-GM1 was obtained from WAKO (Osaka, Japan). Anti-Gr-1 antibody (Nippon Becton Dickinson) was used for depletion of granulocytes. Mice were inoculated with 1 Â 10 5 cells of MC38-IL4 3 days after depletion of leukocytes ( Figure 1, Experiment 4) . Otherwise, leukocytes were depleted from tumor-free mice 25 days after initial inoculation of MC38-IL4. After 3 days, the mice were reinjected contralaterally with 3 Â 10 5 MC38-WT cells (Figure 1, Experiment 5 ). We used four or five mice per each group, and tumor size was measured at least twice weekly. These experiments were performed twice.
Induction of tumor-specific CTL
Mice were initially inoculated with 1 Â 10 5 nonirradiated MC38-IL4 cells on day 0. Subsequently, MC38-immune mice received challenges of 3 Â 10 5 MC38-WT cells on day 28. Splenocytes (3 Â 10 6 cells/ml) were harvested from these mice on day 42 and then stimulated in vitro with irradiated (10 000 rad) MC38-Neo or -IL4 tumor cells (3 Â 10 5 cells/ml). After 7 days, responder cells (1 Â 10 6 cells/ml) were restimulated with irradiated MC38-Neo or -IL4 tumor cells (10 000 rad, 1 Â 10 5 cells/ ml) and irradiated syngeneic naive splenocytes (3000 rad, 1 Â 10 6 cells/ml) in the presence of 50 IU/ml recombinant mouse IL-2 (Becton Dickinson). Cytolytic assays were performed 7 days after the last stimulation using the responder cells as effector cells (Figure 1 , Experiment 6).
Cytolytic assays
Cytolytic assays were performed as described previously. 43 Tumor-stimulated effector cells were assessed for cytolytic activity against MC38-WT and YAC-1 cells in triplicate in 4-h ) and various numbers of effector cells at indicated E:T were plated in 200 ml of CM in each well of 96-well round-bottom plates. 51 Cr-release was measured after a 4-h incubation at 371C. Percentage lysis was determined using the formula: (release in assayÀ spontaneous release) Â 100/(maximum releaseÀsponta-neous release). Maximum release was determined by lysis of labeled target cells with 1% Triton X-100. Spontaneous release was measured by incubating target cells in the absence of effector cells, and was less than 15% of maximum release.
IL-4 gene therapy in combination with IFN-a or IL-12 gene therapy
To evaluate the efficacy of combined cytokine gene therapy of established tumors, we admixed MC38-IL4 with MC38-Neo, -IFNa, or -IL12 cells and injected them in tumor-bearing mice. As described previously, 1 we measured the size of the established MC38-WT tumors in mice before and after treatment. First, B6 mice were inoculated with 1 Â 10 5 nonirradiated MC38-WT cells in the right flank. After 7 days, mice were injected in the left (opposite) flank with 1 Â 10 5 MC38-Neo cells or with one of the following pairs (5 Â 10 4 cells each): MC38-Neo and -IL4; MC38-IL4 and -IFNa; or MC38-IL4 and -IL12. Therapeutic injections were repeated three times at 3-day intervals starting at day 7 ( Figure 1, Experiment 7) . Each experiment involved six mice per group. Tumor size was measured twice a week using vernier calipers. This experiment was repeated three times.
IFN-g and IL-10 production of splenocytes from mice inoculated with cytokine gene-transduced cells
To assess the mechanism of combined cytokine gene therapy of established tumors, we performed ELISA for IFN-g and IL-10. We inoculated mice with 1 Â 10 5 cells each of MC38-Neo, -IL4, or -IFNa, or with 5 Â 10 4 cells each of both MC38-IL4 and -IFNa cells. Then we injected 1 Â 10 5 MC38-WT cells in the opposite flank 2 weeks after the first inoculation ( Figure 1, Experiment 8) . After 7 days, mice were killed and splenocytes from these mice were simulated with each cytokine-overexpressing or control gene-transduced MC38 cell line either alone or in combination, corresponding to the first inoculation in vitro. After 7 days of incubation, we measured IFN-g and IL-10 concentrations in the culture supernatant by ELISA using a commercially available kit according to the manufacturers' instructions (mouse IFN-g ELISA and mouse IL-10 ELISA, Endogen). This experiment was repeated three times.
Statistical analyses
Significance was assessed by Student's t-test. Differences between groups were considered significant when the P-value was lower than 0.05.
